Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

5

Portfolio Exits

1

About Chris Hobbs

Chris Hobbs Headquarters Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Chris Hobbs News

MediPharm Labs Launches LABS CANNABIS, A New and Innovative Family of Health and Wellness Products

Oct 20, 2020

2)  Health Canada, 2020: https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/summary-report-consultation-potential-market-health-products-cannabis.html Corporate and Management UpdateThe Company announced the departure of Sybil Taylor, Chief Marketing Officer and, in addition, Chris Hobbs resigned from the Company’s Board of Directors effective October 19, 2020.About MediPharm LabsFounded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, they formulate, consumer-test, process, package and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.For further information, please contact: Laura Lepore, VP, Investor Relations Telephone: +1 416.913.7425 ext. 1525 Website:  www.medipharmlabs.com CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, the creation of best-in-class products meeting the essential requirements of the most discerning wellness customers; the formulation of specialized offerings including THC and/or other minor cannabinoids that address potential effects; the use of differentiated delivery methods and unique packaging; and rapidly expanding cannabis market and growing consumer demand. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bd765afd-b28d-4a02-ae10-515702e7e416

Chris Hobbs Investments

5 Investments

Chris Hobbs has made 5 investments. Their latest investment was in Hangtime as part of their Seed VC on March 3, 2013.

CBI Logo

Chris Hobbs Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/10/2013

Seed VC

Hangtime

$3.5M

Yes

1

2/21/2013

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

7/11/2012

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

0

3/25/2012

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

3/8/2011

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/10/2013

2/21/2013

7/11/2012

3/25/2012

3/8/2011

Round

Seed VC

Seed VC

Seed VC - II

Seed VC

Seed VC

Company

Hangtime

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$3.5M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

0

10

10

Chris Hobbs Portfolio Exits

1 Portfolio Exit

Chris Hobbs has 1 portfolio exit. Their latest portfolio exit was Wedding Party on August 04, 2015.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/4/2015

Acquired

$99M

1

Date

8/4/2015

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.